Loomis, Sayles & Company’s Enanta Pharmaceuticals ENTA Stock Holding History

Loomis, Sayles & Company’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-90	Closed	-$10K	–	901
2018 Q2	$10K	Hold	90	–	–	﹤0.01%	794
2018 Q1	$7K	Sell	90 -617	-87%	-$47.5K	﹤0.01%	840
2017 Q4	$41K	Buy	707 +21	+3%	+$1.05K	﹤0.01%	627
2017 Q3	$32K	Buy	686 +51	+8%	+$2.05K	﹤0.01%	680
2017 Q2	$23K	Buy	635 +57	+10%	+$1.82K	﹤0.01%	749
2017 Q1	$18K	Sell	578 -61	-10%	-$1.9K	﹤0.01%	779
2016 Q4	$21K	Buy	639 +231	+57%	+$6.62K	﹤0.01%	773
2016 Q3	$11K	Buy	408 +85	+26%	+$1.97K	﹤0.01%	748
2016 Q2	$7K	Buy	323 +256	+382%	+$6.7K	﹤0.01%	796
2016 Q1	$2K	Buy	+67	New	+$1.86K	﹤0.01%	991

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Loomis, Sayles & Company's ENTA Position: Q3 2018 in Review

Loomis, Sayles & Company sold out of Enanta Pharmaceuticals (ENTA) in Q3 2018, closing a stake of 90 shares — an estimated $10K sold.

Loomis, Sayles & Company first reported a position in ENTA in Q1 2016 and held it in 10 quarters. The position peaked at $41K in Q4 2017. 197 funds tracked by Wall St. Rank hold ENTA as of Q3 2018.

Loomis, Sayles & Company reported no remaining Enanta Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Loomis, Sayles & Company sold 90 Enanta Pharmaceuticals shares in Q3 2018, an estimated $10K.
Loomis, Sayles & Company first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 10 quarters.
Loomis, Sayles & Company's Enanta Pharmaceuticals position peaked at $41K in Q4 2017.
197 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2018.

Based on Loomis, Sayles & Company's 13F filing for Q3 2018, filed 13 Nov 2018.